Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate
- PMID: 33082295
- PMCID: PMC7857404
- DOI: 10.1126/science.abe1502
Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate
Abstract
Vaccine efforts to combat the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is responsible for the current coronavirus disease 2019 (COVID-19) pandemic, are focused on SARS-CoV-2 spike glycoprotein, the primary target for neutralizing antibodies. We performed cryo-election microscopy and site-specific glycan analysis of one of the leading subunit vaccine candidates from Novavax, which is based on a full-length spike protein formulated in polysorbate 80 detergent. Our studies reveal a stable prefusion conformation of the spike immunogen with slight differences in the S1 subunit compared with published spike ectodomain structures. We also observed interactions between the spike trimers, allowing formation of higher-order spike complexes. This study confirms the structural integrity of the full-length spike protein immunogen and provides a basis for interpreting immune responses to this multivalent nanoparticle immunogen.
Copyright © 2020, American Association for the Advancement of Science.
Figures




Update of
-
Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate.bioRxiv [Preprint]. 2020 Aug 6:2020.08.06.234674. doi: 10.1101/2020.08.06.234674. bioRxiv. 2020. Update in: Science. 2020 Nov 27;370(6520):1089-1094. doi: 10.1126/science.abe1502. PMID: 32793901 Free PMC article. Updated. Preprint.
Similar articles
-
Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate.bioRxiv [Preprint]. 2020 Aug 6:2020.08.06.234674. doi: 10.1101/2020.08.06.234674. bioRxiv. 2020. Update in: Science. 2020 Nov 27;370(6520):1089-1094. doi: 10.1126/science.abe1502. PMID: 32793901 Free PMC article. Updated. Preprint.
-
Cryo-electron Microscopy Structure of the Swine Acute Diarrhea Syndrome Coronavirus Spike Glycoprotein Provides Insights into Evolution of Unique Coronavirus Spike Proteins.J Virol. 2020 Oct 27;94(22):e01301-20. doi: 10.1128/JVI.01301-20. Print 2020 Oct 27. J Virol. 2020. PMID: 32817223 Free PMC article.
-
SARS-CoV-2 spike produced in insect cells elicits high neutralization titres in non-human primates.Emerg Microbes Infect. 2020 Dec;9(1):2076-2090. doi: 10.1080/22221751.2020.1821583. Emerg Microbes Infect. 2020. PMID: 32897177 Free PMC article.
-
The SARS-CoV-2 Spike Glycoprotein as a Drug and Vaccine Target: Structural Insights into Its Complexes with ACE2 and Antibodies.Cells. 2020 Oct 22;9(11):2343. doi: 10.3390/cells9112343. Cells. 2020. PMID: 33105869 Free PMC article. Review.
-
Severe acute respiratory syndrome-coronavirus-2 spike (S) protein based vaccine candidates: State of the art and future prospects.Rev Med Virol. 2021 May;31(3):e2183. doi: 10.1002/rmv.2183. Epub 2020 Oct 15. Rev Med Virol. 2021. PMID: 33594794 Free PMC article. Review.
Cited by
-
A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability.NPJ Vaccines. 2022 Nov 2;7(1):136. doi: 10.1038/s41541-022-00549-y. NPJ Vaccines. 2022. PMID: 36323666 Free PMC article.
-
Characterization of the SARS-CoV-2 E Protein: Sequence, Structure, Viroporin, and Inhibitors.Protein Sci. 2021 Jun;30(6):1114-1130. doi: 10.1002/pro.4075. Epub 2021 Apr 13. Protein Sci. 2021. PMID: 33813796 Free PMC article. Review.
-
Design of an artificial transcriptional system for production of high levels of recombinant proteins in tobacco (Nicotiana benthamiana).Front Plant Sci. 2023 Feb 23;14:1138089. doi: 10.3389/fpls.2023.1138089. eCollection 2023. Front Plant Sci. 2023. PMID: 36909433 Free PMC article.
-
SARS-CoV-2-Specific Vaccine Candidates; the Contribution of Structural Vaccinology.Vaccines (Basel). 2022 Feb 3;10(2):236. doi: 10.3390/vaccines10020236. Vaccines (Basel). 2022. PMID: 35214693 Free PMC article. Review.
-
A flow cytometry-based neutralization assay for simultaneous evaluation of blocking antibodies against SARS-CoV-2 variants.Front Immunol. 2022 Nov 24;13:1014309. doi: 10.3389/fimmu.2022.1014309. eCollection 2022. Front Immunol. 2022. PMID: 36505411 Free PMC article.
References
-
- Zhu N., Zhang D., Wang W., Li X., Yang B., Song J., Zhao X., Huang B., Shi W., Lu R., Niu P., Zhan F., Ma X., Wang D., Xu W., Wu G., Gao G. F., Tan W., China Novel Coronavirus Investigating and Research Team , A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382, 727–733 (2020). 10.1056/NEJMoa2001017 - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous